| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triple Negative Breast Neoplasms | 7 | 2025 | 287 | 2.670 |
Why?
|
| Mitochondria | 13 | 2025 | 759 | 2.420 |
Why?
|
| src-Family Kinases | 2 | 2025 | 92 | 1.330 |
Why?
|
| Fatty Acids | 9 | 2025 | 377 | 1.270 |
Why?
|
| Cell Line, Tumor | 25 | 2026 | 3692 | 0.950 |
Why?
|
| Biguanides | 1 | 2025 | 12 | 0.900 |
Why?
|
| Breast Neoplasms | 13 | 2024 | 2649 | 0.870 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2025 | 300 | 0.760 |
Why?
|
| Signal Transduction | 8 | 2026 | 4683 | 0.750 |
Why?
|
| DNA, Mitochondrial | 4 | 2014 | 241 | 0.740 |
Why?
|
| Antineoplastic Agents | 5 | 2025 | 1811 | 0.730 |
Why?
|
| Neoplasms | 7 | 2025 | 2966 | 0.730 |
Why?
|
| NF-kappa B | 1 | 2024 | 449 | 0.710 |
Why?
|
| Energy Metabolism | 4 | 2025 | 785 | 0.670 |
Why?
|
| CD24 Antigen | 3 | 2024 | 31 | 0.520 |
Why?
|
| Glycolysis | 5 | 2025 | 171 | 0.500 |
Why?
|
| Oxidative Phosphorylation | 6 | 2025 | 130 | 0.490 |
Why?
|
| Animals | 29 | 2026 | 34404 | 0.390 |
Why?
|
| Honey | 2 | 2002 | 5 | 0.380 |
Why?
|
| AMP-Activated Protein Kinases | 3 | 2025 | 173 | 0.360 |
Why?
|
| Cell Fusion | 1 | 2012 | 34 | 0.360 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2013 | 237 | 0.360 |
Why?
|
| Luminescent Agents | 3 | 2016 | 6 | 0.340 |
Why?
|
| Europium | 3 | 2016 | 6 | 0.340 |
Why?
|
| Cell Proliferation | 8 | 2026 | 2483 | 0.330 |
Why?
|
| Cell Nucleus | 1 | 2013 | 567 | 0.330 |
Why?
|
| Humans | 55 | 2026 | 131759 | 0.330 |
Why?
|
| Mice | 17 | 2026 | 18482 | 0.310 |
Why?
|
| Phosphorylation | 4 | 2024 | 1571 | 0.310 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2026 | 2003 | 0.310 |
Why?
|
| Crohn Disease | 2 | 2023 | 291 | 0.300 |
Why?
|
| Wnt1 Protein | 1 | 2009 | 75 | 0.290 |
Why?
|
| Egg White | 1 | 2008 | 10 | 0.290 |
Why?
|
| Mice, Nude | 2 | 2025 | 714 | 0.290 |
Why?
|
| Cytochrome P-450 CYP2D6 | 3 | 2001 | 34 | 0.280 |
Why?
|
| Carcinogenesis | 3 | 2026 | 357 | 0.270 |
Why?
|
| PPAR alpha | 2 | 2024 | 53 | 0.260 |
Why?
|
| Glucose | 4 | 2025 | 848 | 0.250 |
Why?
|
| Mutation | 6 | 2025 | 6194 | 0.250 |
Why?
|
| Estrogens | 2 | 2009 | 436 | 0.250 |
Why?
|
| Glutamine | 2 | 2025 | 202 | 0.250 |
Why?
|
| Heterozygote | 1 | 2009 | 728 | 0.250 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2024 | 545 | 0.240 |
Why?
|
| DNA-Binding Proteins | 2 | 2009 | 1965 | 0.240 |
Why?
|
| Polymorphism, Genetic | 5 | 2005 | 794 | 0.240 |
Why?
|
| Muscle, Skeletal | 2 | 2025 | 1004 | 0.240 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2026 | 56 | 0.240 |
Why?
|
| Nanotubes | 2 | 2016 | 18 | 0.240 |
Why?
|
| Electron Transport Complex I | 2 | 2024 | 31 | 0.240 |
Why?
|
| DNA Repair | 3 | 2022 | 577 | 0.230 |
Why?
|
| Food-Drug Interactions | 2 | 2002 | 10 | 0.230 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2025 | 999 | 0.230 |
Why?
|
| RNA-Binding Proteins | 1 | 2009 | 550 | 0.220 |
Why?
|
| Dasatinib | 1 | 2025 | 53 | 0.220 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2024 | 5 | 0.220 |
Why?
|
| Metabolic Networks and Pathways | 3 | 2025 | 193 | 0.220 |
Why?
|
| Pentacyclic Triterpenes | 1 | 2024 | 8 | 0.220 |
Why?
|
| Glutaminase | 1 | 2024 | 18 | 0.220 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2025 | 72 | 0.210 |
Why?
|
| Oncolytic Viruses | 1 | 2025 | 75 | 0.210 |
Why?
|
| Transcriptome | 3 | 2025 | 1148 | 0.210 |
Why?
|
| Oncolytic Virotherapy | 1 | 2025 | 90 | 0.210 |
Why?
|
| Ileitis | 1 | 2023 | 10 | 0.210 |
Why?
|
| Adenosine Triphosphate | 4 | 2022 | 265 | 0.210 |
Why?
|
| Female | 24 | 2025 | 71214 | 0.210 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 145 | 0.200 |
Why?
|
| Carcinogens | 2 | 2017 | 129 | 0.200 |
Why?
|
| DNA Damage | 2 | 2017 | 527 | 0.200 |
Why?
|
| Metformin | 1 | 2025 | 168 | 0.190 |
Why?
|
| Diltiazem | 1 | 2002 | 14 | 0.190 |
Why?
|
| Adipogenesis | 1 | 2023 | 80 | 0.190 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2016 | 245 | 0.190 |
Why?
|
| Rhabdomyosarcoma | 1 | 2026 | 228 | 0.190 |
Why?
|
| Cells, Cultured | 1 | 2008 | 2969 | 0.190 |
Why?
|
| Carbamazepine | 1 | 2002 | 43 | 0.190 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 713 | 0.180 |
Why?
|
| Life Style | 1 | 2025 | 444 | 0.180 |
Why?
|
| Rothmund-Thomson Syndrome | 1 | 2021 | 48 | 0.180 |
Why?
|
| RecQ Helicases | 1 | 2021 | 63 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 4 | 2008 | 1489 | 0.180 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 704 | 0.180 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2019 | 738 | 0.170 |
Why?
|
| Stomach Ulcer | 4 | 2001 | 94 | 0.170 |
Why?
|
| Ataxia Telangiectasia | 1 | 2021 | 14 | 0.170 |
Why?
|
| Mutant Proteins | 2 | 2019 | 113 | 0.170 |
Why?
|
| Duodenal Ulcer | 4 | 2001 | 126 | 0.170 |
Why?
|
| Cell Differentiation | 2 | 2026 | 1948 | 0.170 |
Why?
|
| Hypogonadism | 1 | 2025 | 323 | 0.170 |
Why?
|
| Kidney Neoplasms | 2 | 2016 | 454 | 0.170 |
Why?
|
| Obesity | 2 | 2025 | 2390 | 0.160 |
Why?
|
| Mice, SCID | 3 | 2016 | 579 | 0.160 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2021 | 100 | 0.160 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2021 | 42 | 0.160 |
Why?
|
| Autophagy | 2 | 2016 | 424 | 0.160 |
Why?
|
| Glioma | 1 | 2025 | 498 | 0.160 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1617 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2013 | 1236 | 0.160 |
Why?
|
| Oxidation-Reduction | 2 | 2023 | 442 | 0.160 |
Why?
|
| Computational Biology | 1 | 2025 | 872 | 0.160 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2019 | 30 | 0.160 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2019 | 427 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2018 | 195 | 0.150 |
Why?
|
| Neoplastic Stem Cells | 3 | 2021 | 329 | 0.150 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2021 | 260 | 0.150 |
Why?
|
| Reactive Oxygen Species | 3 | 2025 | 518 | 0.150 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2023 | 328 | 0.150 |
Why?
|
| Estrogen Receptor beta | 1 | 2019 | 77 | 0.150 |
Why?
|
| Resistance Training | 1 | 2019 | 26 | 0.150 |
Why?
|
| Anticonvulsants | 1 | 2002 | 391 | 0.150 |
Why?
|
| Testosterone | 1 | 2025 | 604 | 0.150 |
Why?
|
| Pyruvic Acid | 1 | 2019 | 37 | 0.150 |
Why?
|
| RNA, Long Noncoding | 1 | 2021 | 231 | 0.150 |
Why?
|
| Osteosarcoma | 1 | 2021 | 265 | 0.150 |
Why?
|
| India | 5 | 2005 | 245 | 0.140 |
Why?
|
| Carbon Isotopes | 1 | 2019 | 230 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2024 | 826 | 0.140 |
Why?
|
| Antioxidants | 1 | 2021 | 336 | 0.140 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2019 | 95 | 0.140 |
Why?
|
| Optical Imaging | 2 | 2016 | 76 | 0.140 |
Why?
|
| Gastric Acid | 4 | 2001 | 55 | 0.140 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2018 | 22 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2024 | 639 | 0.140 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2023 | 404 | 0.140 |
Why?
|
| X-Box Binding Protein 1 | 1 | 2018 | 28 | 0.140 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2019 | 254 | 0.140 |
Why?
|
| Response Elements | 1 | 2018 | 99 | 0.130 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Kinase | 1 | 2018 | 54 | 0.130 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2017 | 32 | 0.130 |
Why?
|
| Models, Biological | 4 | 2025 | 1395 | 0.130 |
Why?
|
| Mutagens | 1 | 2017 | 48 | 0.130 |
Why?
|
| Endoribonucleases | 1 | 2018 | 86 | 0.130 |
Why?
|
| Inflammation | 2 | 2023 | 1493 | 0.130 |
Why?
|
| Tobacco Products | 1 | 2017 | 61 | 0.130 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 212 | 0.130 |
Why?
|
| Hexosamines | 1 | 2016 | 18 | 0.120 |
Why?
|
| Nanotechnology | 1 | 2016 | 50 | 0.120 |
Why?
|
| Muscle Proteins | 1 | 2019 | 404 | 0.120 |
Why?
|
| Chloroquine | 1 | 2016 | 31 | 0.120 |
Why?
|
| Cell Survival | 3 | 2013 | 854 | 0.120 |
Why?
|
| DNA Mutational Analysis | 2 | 2014 | 803 | 0.120 |
Why?
|
| Estrogen Receptor alpha | 2 | 2010 | 434 | 0.120 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 180 | 0.120 |
Why?
|
| Gadolinium | 1 | 2016 | 112 | 0.120 |
Why?
|
| Cell Line | 3 | 2019 | 2606 | 0.120 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 835 | 0.120 |
Why?
|
| Brain Neoplasms | 1 | 2025 | 1297 | 0.120 |
Why?
|
| Molecular Imaging | 2 | 2015 | 61 | 0.120 |
Why?
|
| Prostate | 1 | 2018 | 415 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 403 | 0.110 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 361 | 0.110 |
Why?
|
| Graphite | 2 | 2012 | 15 | 0.110 |
Why?
|
| Apoptosis | 3 | 2017 | 1861 | 0.110 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2005 | 66 | 0.110 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2005 | 40 | 0.110 |
Why?
|
| Mixed Function Oxygenases | 1 | 2005 | 37 | 0.110 |
Why?
|
| Tissue Fixation | 1 | 2005 | 38 | 0.110 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2016 | 100 | 0.110 |
Why?
|
| Hyaluronan Receptors | 1 | 2005 | 65 | 0.110 |
Why?
|
| HeLa Cells | 2 | 2021 | 694 | 0.110 |
Why?
|
| Receptors, Androgen | 1 | 2018 | 419 | 0.110 |
Why?
|
| Gene Deletion | 2 | 2010 | 773 | 0.110 |
Why?
|
| Phosphates | 1 | 2015 | 110 | 0.110 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2005 | 299 | 0.110 |
Why?
|
| DNA | 2 | 2022 | 1442 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 4 | 2014 | 1218 | 0.110 |
Why?
|
| Biocompatible Materials | 1 | 2015 | 122 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 356 | 0.100 |
Why?
|
| Drug Design | 1 | 2015 | 166 | 0.100 |
Why?
|
| Prognosis | 3 | 2019 | 4953 | 0.100 |
Why?
|
| Hybrid Cells | 1 | 2013 | 78 | 0.100 |
Why?
|
| DNA Methylation | 2 | 2017 | 1087 | 0.100 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 85 | 0.100 |
Why?
|
| Exercise | 1 | 2019 | 866 | 0.100 |
Why?
|
| Receptors, Estrogen | 2 | 2022 | 723 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2005 | 418 | 0.100 |
Why?
|
| Yttrium | 1 | 2012 | 6 | 0.100 |
Why?
|
| Paneth Cells | 2 | 2023 | 23 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 421 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 1008 | 0.090 |
Why?
|
| Heterografts | 1 | 2013 | 195 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 125 | 0.090 |
Why?
|
| Half-Life | 2 | 2002 | 151 | 0.090 |
Why?
|
| Smoking | 1 | 2017 | 926 | 0.090 |
Why?
|
| Ethidium | 1 | 2012 | 5 | 0.090 |
Why?
|
| Uridine | 1 | 2012 | 31 | 0.090 |
Why?
|
| Quantum Dots | 1 | 2012 | 15 | 0.090 |
Why?
|
| Metal Nanoparticles | 1 | 2012 | 55 | 0.090 |
Why?
|
| Vasotocin | 2 | 2001 | 2 | 0.090 |
Why?
|
| Nanostructures | 1 | 2012 | 64 | 0.090 |
Why?
|
| Doxorubicin | 1 | 2013 | 301 | 0.090 |
Why?
|
| Area Under Curve | 2 | 2002 | 320 | 0.090 |
Why?
|
| Rabbits | 2 | 2002 | 633 | 0.090 |
Why?
|
| Rats | 6 | 2024 | 3460 | 0.090 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2009 | 233 | 0.090 |
Why?
|
| Carbon | 1 | 2012 | 94 | 0.090 |
Why?
|
| Phenotype | 5 | 2025 | 4528 | 0.090 |
Why?
|
| Oxytocin | 2 | 2001 | 71 | 0.080 |
Why?
|
| Anti-Ulcer Agents | 2 | 2001 | 115 | 0.080 |
Why?
|
| Gene Frequency | 3 | 2005 | 750 | 0.080 |
Why?
|
| Genetic Markers | 1 | 2012 | 605 | 0.080 |
Why?
|
| Nuclear Matrix-Associated Proteins | 1 | 2009 | 18 | 0.080 |
Why?
|
| Transfection | 1 | 2012 | 960 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 611 | 0.080 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2009 | 18 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2018 | 1418 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2007 | 2860 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3916 | 0.070 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2009 | 52 | 0.070 |
Why?
|
| Immunity | 1 | 2009 | 179 | 0.070 |
Why?
|
| Male | 13 | 2025 | 65274 | 0.070 |
Why?
|
| Egg Proteins | 1 | 2008 | 29 | 0.070 |
Why?
|
| Contrast Media | 1 | 2012 | 491 | 0.070 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2008 | 53 | 0.070 |
Why?
|
| Proteoglycans | 1 | 2008 | 79 | 0.070 |
Why?
|
| Risk | 1 | 2010 | 739 | 0.070 |
Why?
|
| Hydroxamic Acids | 1 | 2008 | 59 | 0.070 |
Why?
|
| Neoplasms, Experimental | 1 | 2009 | 205 | 0.070 |
Why?
|
| Laminin | 1 | 2008 | 68 | 0.070 |
Why?
|
| Cell Movement | 2 | 2026 | 886 | 0.070 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2008 | 83 | 0.070 |
Why?
|
| Nanoparticles | 2 | 2024 | 292 | 0.070 |
Why?
|
| Genomics | 1 | 2016 | 1626 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2016 | 2569 | 0.070 |
Why?
|
| Drug Combinations | 1 | 2008 | 280 | 0.070 |
Why?
|
| Metabolomics | 2 | 2024 | 493 | 0.070 |
Why?
|
| Genetics, Population | 2 | 2005 | 185 | 0.070 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2009 | 323 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2019 | 3864 | 0.060 |
Why?
|
| Collagen | 1 | 2008 | 289 | 0.060 |
Why?
|
| Genotype | 3 | 2005 | 2656 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2008 | 659 | 0.060 |
Why?
|
| Anthracyclines | 2 | 2007 | 43 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 566 | 0.060 |
Why?
|
| Lipid Peroxidation | 1 | 2025 | 91 | 0.060 |
Why?
|
| Hemochromatosis | 1 | 2005 | 39 | 0.060 |
Why?
|
| Luminescent Measurements | 2 | 2016 | 56 | 0.050 |
Why?
|
| Prolactin | 2 | 2001 | 112 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2016 | 344 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2016 | 198 | 0.050 |
Why?
|
| Iron | 2 | 2023 | 310 | 0.050 |
Why?
|
| Dextromethorphan | 2 | 2001 | 11 | 0.050 |
Why?
|
| Base Sequence | 3 | 2014 | 2783 | 0.050 |
Why?
|
| Butyrates | 1 | 2023 | 41 | 0.050 |
Why?
|
| Flavin-Adenine Dinucleotide | 1 | 2023 | 9 | 0.050 |
Why?
|
| Flavoproteins | 1 | 2023 | 20 | 0.050 |
Why?
|
| Ceramides | 1 | 2023 | 46 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2016 | 482 | 0.050 |
Why?
|
| Adult | 7 | 2021 | 31700 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 1398 | 0.050 |
Why?
|
| Survival Rate | 2 | 2019 | 2151 | 0.050 |
Why?
|
| Phosphofructokinase-1 | 1 | 2022 | 6 | 0.050 |
Why?
|
| Bone Density | 1 | 2025 | 362 | 0.050 |
Why?
|
| Cell Respiration | 1 | 2021 | 24 | 0.050 |
Why?
|
| Fasting | 1 | 2023 | 303 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2025 | 685 | 0.050 |
Why?
|
| Oxadiazoles | 1 | 2021 | 25 | 0.050 |
Why?
|
| Hormone Replacement Therapy | 1 | 2025 | 215 | 0.050 |
Why?
|
| Citric Acid Cycle | 1 | 2022 | 43 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2026 | 633 | 0.040 |
Why?
|
| Hyperprolactinemia | 1 | 2001 | 23 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 89 | 0.040 |
Why?
|
| Pituitary Gland | 1 | 2001 | 79 | 0.040 |
Why?
|
| Tamoxifen | 2 | 2010 | 350 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2002 | 549 | 0.040 |
Why?
|
| Enterocytes | 1 | 2021 | 68 | 0.040 |
Why?
|
| Osteoblasts | 1 | 2021 | 158 | 0.040 |
Why?
|
| Rats, Wistar | 4 | 2001 | 309 | 0.040 |
Why?
|
| Osteogenesis | 1 | 2021 | 167 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 1626 | 0.040 |
Why?
|
| Epithelium | 1 | 2021 | 343 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2002 | 709 | 0.040 |
Why?
|
| Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2019 | 5 | 0.040 |
Why?
|
| Piperidines | 1 | 2021 | 231 | 0.040 |
Why?
|
| DNA Primers | 2 | 2011 | 609 | 0.040 |
Why?
|
| Cellular Senescence | 1 | 2021 | 218 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 6915 | 0.040 |
Why?
|
| Stomach | 1 | 2001 | 274 | 0.040 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2021 | 253 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2021 | 322 | 0.040 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2019 | 73 | 0.040 |
Why?
|
| Aged | 4 | 2025 | 21259 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2019 | 5122 | 0.040 |
Why?
|
| Drosophila | 1 | 2023 | 795 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 172 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2023 | 765 | 0.040 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 160 | 0.040 |
Why?
|
| Middle Aged | 5 | 2024 | 28892 | 0.040 |
Why?
|
| Metribolone | 1 | 2018 | 28 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2005 | 1561 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2021 | 364 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2021 | 371 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 989 | 0.030 |
Why?
|
| Unfolded Protein Response | 1 | 2018 | 63 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 1356 | 0.030 |
Why?
|
| Butanones | 1 | 2017 | 7 | 0.030 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2017 | 12 | 0.030 |
Why?
|
| Nitrosamines | 1 | 2017 | 15 | 0.030 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2017 | 25 | 0.030 |
Why?
|
| Benzo(a)pyrene | 1 | 2017 | 24 | 0.030 |
Why?
|
| Acetic Acid | 3 | 2001 | 17 | 0.030 |
Why?
|
| Cysteamine | 3 | 2001 | 15 | 0.030 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2007 | 19 | 0.030 |
Why?
|
| Pylorus | 3 | 2001 | 20 | 0.030 |
Why?
|
| Azacitidine | 1 | 2017 | 51 | 0.030 |
Why?
|
| Biopsy | 1 | 2021 | 1252 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 3616 | 0.030 |
Why?
|
| DNA Adducts | 1 | 2017 | 71 | 0.030 |
Why?
|
| Indomethacin | 3 | 2001 | 81 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2017 | 9 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2021 | 1005 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 82 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2007 | 134 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 277 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2019 | 366 | 0.030 |
Why?
|
| Magnets | 1 | 2016 | 19 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2017 | 301 | 0.030 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2017 | 79 | 0.030 |
Why?
|
| Electron Transport Complex IV | 1 | 2016 | 41 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2016 | 46 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2007 | 203 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 393 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 1835 | 0.030 |
Why?
|
| Carboplatin | 1 | 2016 | 80 | 0.030 |
Why?
|
| Superoxides | 1 | 2016 | 129 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 665 | 0.030 |
Why?
|
| Androgens | 1 | 2018 | 272 | 0.030 |
Why?
|
| Liver | 1 | 2023 | 1799 | 0.030 |
Why?
|
| Haplotypes | 1 | 2007 | 550 | 0.030 |
Why?
|
| Taq Polymerase | 1 | 2005 | 7 | 0.030 |
Why?
|
| Weight Loss | 1 | 2019 | 529 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 239 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2018 | 405 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2005 | 7 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 910 | 0.030 |
Why?
|
| Methotrexate | 1 | 2007 | 342 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2005 | 42 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2005 | 41 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2005 | 27 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2005 | 138 | 0.030 |
Why?
|
| Breast Diseases | 1 | 2005 | 38 | 0.030 |
Why?
|
| Kidney | 1 | 2001 | 1309 | 0.030 |
Why?
|
| Metabolome | 1 | 2017 | 329 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2014 | 82 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2014 | 121 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2005 | 286 | 0.030 |
Why?
|
| Telomerase | 1 | 2014 | 157 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 418 | 0.030 |
Why?
|
| Chronic Disease | 3 | 2001 | 1235 | 0.020 |
Why?
|
| Chromatin | 1 | 2016 | 491 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 4685 | 0.020 |
Why?
|
| X-Ray Diffraction | 1 | 2012 | 101 | 0.020 |
Why?
|
| Oxides | 1 | 2012 | 16 | 0.020 |
Why?
|
| Histones | 1 | 2016 | 533 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2012 | 134 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2016 | 900 | 0.020 |
Why?
|
| Solubility | 1 | 2012 | 118 | 0.020 |
Why?
|
| Surface Properties | 1 | 2012 | 83 | 0.020 |
Why?
|
| Fluorescence | 1 | 2012 | 97 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2012 | 111 | 0.020 |
Why?
|
| Particle Size | 1 | 2012 | 137 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 1610 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 428 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2014 | 652 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 1260 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2005 | 1521 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2005 | 677 | 0.020 |
Why?
|
| Histone Deacetylase 1 | 1 | 2010 | 20 | 0.020 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2010 | 39 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2010 | 82 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2012 | 579 | 0.020 |
Why?
|
| Ethanol | 2 | 2001 | 164 | 0.020 |
Why?
|
| Alleles | 1 | 2005 | 1711 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2010 | 213 | 0.020 |
Why?
|
| Co-Repressor Proteins | 1 | 2009 | 38 | 0.020 |
Why?
|
| Exome | 1 | 2014 | 1076 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 291 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2016 | 895 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 1023 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2010 | 414 | 0.020 |
Why?
|
| Acute Disease | 2 | 2001 | 1153 | 0.020 |
Why?
|
| Estradiol | 1 | 2010 | 481 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 3696 | 0.020 |
Why?
|
| RNA Interference | 1 | 2009 | 496 | 0.020 |
Why?
|
| Genome, Human | 1 | 2014 | 1331 | 0.020 |
Why?
|
| Brain | 1 | 2019 | 3235 | 0.020 |
Why?
|
| Binding Sites | 1 | 2009 | 1202 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 6280 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 2565 | 0.010 |
Why?
|
| Germany | 1 | 2005 | 55 | 0.010 |
Why?
|
| Menopause | 1 | 2005 | 87 | 0.010 |
Why?
|
| Child | 1 | 2023 | 26307 | 0.010 |
Why?
|
| Ranitidine | 1 | 2001 | 30 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 2001 | 157 | 0.010 |
Why?
|
| Gastric Acidity Determination | 1 | 2001 | 24 | 0.010 |
Why?
|
| Injections, Intraventricular | 1 | 2001 | 53 | 0.010 |
Why?
|
| Adolescent | 1 | 2000 | 20987 | 0.010 |
Why?
|
| Histamine | 1 | 2001 | 52 | 0.010 |
Why?
|
| Receptors, Oxytocin | 1 | 2001 | 22 | 0.010 |
Why?
|
| Ligation | 1 | 2001 | 137 | 0.010 |
Why?
|
| Injections, Spinal | 1 | 2001 | 132 | 0.010 |
Why?
|
| Duodenum | 1 | 2001 | 112 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 4768 | 0.010 |
Why?
|
| Logistic Models | 1 | 2005 | 1838 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2001 | 670 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2005 | 12993 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2007 | 17662 | 0.010 |
Why?
|
| Gastric Mucosa | 1 | 2001 | 491 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2005 | 3451 | 0.010 |
Why?
|
| Incidence | 1 | 2005 | 3349 | 0.010 |
Why?
|
| Risk Factors | 1 | 2005 | 10961 | 0.010 |
Why?
|
| Pregnancy | 1 | 2001 | 7576 | 0.000 |
Why?
|